Cole Sterling
Internal Medicine · Baltimore, MDNPI 1114317344
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,000 of the $1,448 with a category attached, or 69.1%. Kyowa Kirin, Inc. accounts for 89.9% of it on its own, with 1 other manufacturer making up the rest.
Across 7 payments — averaging $206.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$1K
- Sobi, Inc$146
Across 5 payments — averaging $11,607 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$45K
- Taiho Oncology, Inc.$8K
- Pfizer$5K
What the payments were for
- Consulting fees$1,00069%
- Food & beverage$30221%
- Education$14610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 5 | $1,302 |
| Sobi, Inc | 2 | $146 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- POTELIGEO$223
How this compares
$1,448 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 20 | $292,050 |
| RevlimidLenalidomide | 15 | $227,016 |
| JakafiRuxolitinib Phosphate | 14 | $216,943 |
| Atovaquone | 17 | $10,729 |
| ValacyclovirValacyclovir Hcl | 45 | $4,514 |
| Allopurinol | 19 | $133 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $81 |
| Prednisone | 27 | $74 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Baltimore
- Param DedhiaBaltimore$636K
- Shawn DhillonBaltimore$227K
- Jeremy SugarmanBaltimore$210K
- Charles FlexnerBaltimore$133K
- Kristen MarroneBaltimore$97K
- Ana-Maria OrbaiBaltimore$89K
- Mark YarchoanBaltimore$89K
- David Muniz PedrogoBaltimore$82K
- Julie PaikBaltimore$76K
- Allison AgwuBaltimore$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.